News
Biogen beat Q2 estimates with cost control and new launches, but MS declines and pipeline risks cloud growth. Find out why ...
A gene-matched Alzheimer’s drug that slows early symptoms is now approved for use. Patients will need genetic screening, fortnightly infusions, and regular brain scans to stay on treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results